Big Pharma Challenged to Redefine Corporate Social Responsibility Beyond Donations

HARARE – Pharmaceutical companies must move beyond traditional corporate social responsibility and address the needs of chronic patients who are often forgotten, according to Professor Rudo Makunike-Mutasa, who presented a provocative examination of the sector's shared corporate responsibility. 

While CSR typically involves clean-up campaigns, employee schemes, scholarships, career guidance, tree planting and medical outreach, the pharmaceutical industry has a unique opportunity to make a meaningful difference through targeted interventions that go beyond conventional philanthropy.

Professor Makunike-Mutasa, drawing on her extensive medical and scientific background, questioned whether the pharmaceutical sector is doing enough, citing the biblical principle "to whom much is given, much is expected." 

She noted that Big Pharma is often perceived as driven by high prices, huge profits, patent controls, and heartless lawsuits, creating a trust deficit that undermines the industry's reputation. 

However, she argued that the journey from science major to doctor, specialist, professor, and social scientist has given her a unique perspective on both the discoveries and the gaps in pharmaceutical care.

The presentation highlighted ground-breaking pharmaceutical discoveries including HAART in 1996, Trastuzumab in 1998, Imatinib in 2001, checkpoint inhibitors in 2011, Sofosbuvir in 2013, and CAR T-cell therapy in 2017, alongside vaccines that have transformed global health. 

However, Professor Makunike-Mutasa stressed that the cursed poor and chronic patients remain excluded from these advances, creating a moral imperative for the pharmaceutical industry to rethink its approach to corporate responsibility.

She warned that CSR in pharmaceuticals must not become a dumping ground, an advertising portal, or a political gimmick, but instead should be a genuine commitment to making a difference. 

The professor emphasized that transparency, regulation, and integrity are essential pillars for rebuilding trust and ensuring that pharmaceutical companies live up to their shared corporate responsibility to all segments of society.